Dr. Jeffrey Freitag named chief medical officer of PharmaNet

Tuesday, March 8, 2011 10:57 AM

PharmaNet Development Group, a provider of pharmaceutical services to biotechnology, generic drug and medical device companies, has promoted Jeffrey Freitag, M.D., senior vice president of PharmaNet Consulting, to chief medical officer.

Dr. Freitag will be the senior medical representative and guide physicians involved in phase I through phase III clinical trials. He will retain his current responsibilities heading the team of regulatory and pharmaceutical consultants.

Dr. Freitag has worked in the pharmaceutical industry for more than 25 years, including positions as vice president of clinical drug development at The Liposome Company and vice president of R&D at Bone Care International.  He is board certified in Internal Medicine and Nephrology.





Browse by:


December 22

DaVita combines its two research CRO units to create an end-to-end CRO focused on kidney, end-stage renal disease

New crop of clinical trial matching services use patient’s molecular, genomic data for better fit

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs